A Swedish court has ruled that a product containing CBD for oral consumption cannot automatically be classified as a pharmaceutical, but that the legal status of each product must be assessed individually ...
Get access to premium content that is normally only available for subscribers. For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.
Stay informed of any legal and market change in the sector that impacts your organization
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization
Sign up to our newsletter
Subscribe for the latest industry updates
Signup for our newsletter and keep an eye on the latest news!
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.